Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease

被引:56
|
作者
Martinez-Martin, Pablo [1 ,2 ]
Leentjens, Albert F. G. [3 ]
de Pedro-Cuesta, Jesus [1 ,2 ]
Chaudhuri, Kallol Ray [4 ,5 ,6 ,7 ]
Schrag, Anette E. [8 ]
Weintraub, Daniel [9 ,10 ,11 ]
机构
[1] Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain
[2] Carlos III Inst Hlth, CIBERNED, Madrid 28029, Spain
[3] Maastricht Univ, Med Ctr, Dept Psychiat, NL-6200 MD Maastricht, Netherlands
[4] Kings Coll London, Natl Parkinson Fdn Int Ctr Excellence, London WC2R 2LS, England
[5] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Mental Hlth Biomed Res Ctr, London, England
[6] South London & Maudsley NHS Fdn Trust, Dementia Unit, London, England
[7] Kings Coll London, London WC2R 2LS, England
[8] UCL, Inst Neurol, Royal Free Campus, London, England
[9] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA
[10] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[11] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA
关键词
Parkinson's disease; neuropsychiatric symptoms; screening; instruments; accuracy; GERIATRIC DEPRESSION SCALE; IMPULSIVE-COMPULSIVE DISORDERS; DRUG-INDUCED PSYCHOSIS; ANXIETY RATING-SCALES; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS; HOSPITAL ANXIETY; RECOGNIZING DEPRESSION; REPETITIVE BEHAVIORS; ALZHEIMERS-DISEASE;
D O I
10.1002/mds.26522
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease includes neuropsychiatric manifestations, such as depression, anxiety, apathy, psychosis, and impulse control disorders, which often are unreported by patients and caregivers or undetected by doctors. Given their substantial impact on patients and caregivers as well as the existence of effective therapies for some of these disorders, screening for neuropsychiatric symptoms is important. Instruments for screening have a particular methodology for validation, and their performance is expressed in terms of accuracy compared with formal diagnostic criteria. The present study reviews the attributes of the screening instruments applied for detection of the aforementioned major neuropsychiatric symptoms in Parkinson's disease. A quasi-systematic review (including predefined selection criteria, but not evaluating the quality of the reviewed studies) was carried out on the basis of previous systematic reviews (commissioned by the American Academy of Neurology and the Movement Disorder Society) and made current by conducting a literature search (2005-2014). For depression, 11 scales and questionnaires were shown to be valid for Parkinson's disease screening. The recently developed Parkinson Anxiety Scale and the Geriatric Anxiety Inventory demonstrate satisfactory properties as screening instruments for anxiety, and the Lille Apathy Rating Scale for detection of apathy. No scale adequately screens for psychosis, so a specific psychosis instrument should be developed. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (Questionnaire and Rating Scale) are valid for comprehensive screening of impulse control disorders, and the Parkinson's Disease-Sexual Addiction Screening Test for hypersexuality specifically. (c) 2015 International Parkinson and Movement Disorder Society
引用
收藏
页码:270 / 279
页数:10
相关论文
共 50 条
  • [41] Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents
    Decourt, Melina
    Jimenez-Urbieta, Haritz
    Benoit-Marand, Marianne
    Fernagut, Pierre-Olivier
    BIOMEDICINES, 2021, 9 (06)
  • [42] Olfactory Dysfunction Is Associated with Neuropsychiatric Manifestations in Parkinson's Disease
    Morley, James F.
    Weintraub, Daniel
    Mamikonyan, Eugenia
    Moberg, Paul J.
    Siderowf, Andrew D.
    Duda, John E.
    MOVEMENT DISORDERS, 2011, 26 (11) : 2051 - 2057
  • [44] Neuropsychiatric Symptoms Are Associated with Dementia in Parkinson's Disease but Not Predictive of it
    Horne, Kyla-Louise
    MacAskill, Michael R.
    Myall, Daniel J.
    Livingston, Leslie
    Grenfell, Sophie
    Pascoe, Maddie J.
    Young, Bob
    Shoorangiz, Reza
    Melzer, Tracy R.
    Pitcher, Toni L.
    Anderson, Tim J.
    Dalrymple-Alford, John C.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2021, 8 (03): : 390 - 399
  • [45] The Clinical Spectrum of Anxiety in Parkinson's Disease
    Dissanayaka, Nadeeka N. N. W.
    White, Elizabeth
    O'Sullivan, John D.
    Marsh, Rodney
    Pachana, Nancy A.
    Byrne, Gerard J.
    MOVEMENT DISORDERS, 2014, 29 (08) : 967 - 975
  • [46] A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach
    Martinez-Martin, Pablo
    Frades-Payo, Belen
    Agueera-Ortiz, Luis
    Ayuga-Martinez, Angel
    JOURNAL OF NEUROLOGY, 2012, 259 (11) : 2299 - 2308
  • [47] Neuropsychiatric Symptoms in Parkinson's Disease After Subthalamic Nucleus Deep Brain Stimulation
    Liu, Weibing
    Yamamoto, Tatsuya
    Yamanaka, Yoshitaka
    Asahina, Masato
    Uchiyama, Tomoyuki
    Hirano, Shigeki
    Shimizu, Keisuke
    Higuchi, Yoshinori
    Kuwabara, Satoshi
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [48] The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia
    Lee, Wei-Ju
    Tsai, Chia-Fen
    Gauthier, Serge
    Wang, Shuu-Jiun
    Fuh, Jong-Ling
    INTERNATIONAL PSYCHOGERIATRICS, 2012, 24 (12) : 1980 - 1987
  • [49] Depression differentially affects patient and caregiver perceptions of neuropsychiatric symptoms in Parkinson's disease
    Crowley, Brittany Z.
    Patrie, James
    Sperling, Scott A.
    CLINICAL NEUROPSYCHOLOGIST, 2023, 37 (06) : 1191 - 1206
  • [50] Symptom dimensions of anxiety in Parkinson's disease: Replication study in a neuropsychiatric patient population
    Rutten, Sonja
    van Wegen, Erwin E. H.
    Ghielen, Ires
    Schoon, Bridget
    van den Heuvel, Odile A.
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2021, 5